Damoctocog alfa pegol: Difference between revisions
m Wikifying |
mNo edit summary |
||
Line 105: | Line 105: | ||
The most common side effects include headache, cough, nausea and fever.<ref name="Jivi FDA label" /> |
The most common side effects include headache, cough, nausea and fever.<ref name="Jivi FDA label" /> |
||
Damoctocog alfa pegol ( |
Damoctocog alfa pegol (antihemophilic factor- recombinant pegylated-aucl) was approved for medical use in the United States in August 2018,<ref name="Jivi FDA">{{cite web | title=Jivi | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 August 2018 | url=https://www.fda.gov/vaccines-blood-biologics/jivi | access-date=1 October 2020 | id=STN: BL 125661 }} {{PD-notice}}</ref> and in the European Union in November 2018.<ref name="Jivi EPAR" /><ref name="Paik_2019">{{cite journal | vauthors = Paik J, Deeks ED | title = Damoctocog Alfa Pegol: A Review in Haemophilia A | journal = Drugs | volume = 79 | issue = 10 | pages = 1147–1156 | date = July 2019 | pmid = 31218660 | pmc = 6711950 | doi = 10.1007/s40265-019-01152-7 }}</ref> |
||
__TOC__ |
__TOC__ |
||
== Medical uses == |
== Medical uses == |
Revision as of 04:01, 15 November 2023
Clinical data | |
---|---|
Trade names | Jivi |
Other names | BAY94-9027, antihemophilic factor (recombinant), PEGylated-aucl |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C7445H11318N1984O2184S69 |
Molar mass | 165774.28 g·mol−1 |
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate medication used to treat hemophilia A.[4][5]
The most common side effects include headache, cough, nausea and fever.[4]
Damoctocog alfa pegol (antihemophilic factor- recombinant pegylated-aucl) was approved for medical use in the United States in August 2018,[6] and in the European Union in November 2018.[5][7]
Medical uses
In the United States damoctocog alfa pegol is indicated for use in previously treated adults and adolescents (twelve years of age and older) with hemophilia A (congenital Factor VIII deficiency) for: (1) On-demand treatment and control of bleeding episodes ; (2) Perioperative management of bleeding; (3) Routine prophylaxis to reduce the frequency of bleeding episodes.[6]
In the European Union, damoctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in previously treated people twelve years of age and older with haemophilia A (congenital factor VIII deficiency).[5]
References
- ^ a b "Jivi". Therapeutic Goods Administration (TGA). 6 April 2023. Retrieved 7 April 2023.
- ^ "Jivi damoctocog alfa pegol 250 IU powder for injection vial with diluent syringe (384590)". Therapeutic Goods Administration (TGA). 28 March 2023. Retrieved 7 April 2023.
- ^ "Search Page - Drug and Health Product Register". 23 October 2014.
- ^ a b c "Jivi (antihemophilic factor- recombinant pegylated-aucl kit". DailyMed. 30 August 2018. Retrieved 1 October 2020.
- ^ a b c d "Jivi EPAR". European Medicines Agency (EMA). 24 September 2018. Retrieved 1 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Jivi". U.S. Food and Drug Administration (FDA). 29 August 2018. STN: BL 125661. Retrieved 1 October 2020.
This article incorporates text from this source, which is in the public domain.
- ^ Paik J, Deeks ED (July 2019). "Damoctocog Alfa Pegol: A Review in Haemophilia A". Drugs. 79 (10): 1147–1156. doi:10.1007/s40265-019-01152-7. PMC 6711950. PMID 31218660.
External links
- "Damoctocog alfa pegol". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT01184820 for "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration" at ClinicalTrials.gov
- Clinical trial number NCT01580293 for "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)" at ClinicalTrials.gov
- Clinical trial number NCT01775618 for "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A" at ClinicalTrials.gov